relcobatinib
AssetAlso ELVN-001
Small molecule allosteric inhibitor of BCR-ABL1 tyrosine kinase
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- BCR
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Chronic myeloid leukemia
Phase 3, prnewswire.com, 6 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets1
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 1 source